이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hanall Biopharma 미래 성장

Future 기준 확인 4/6

Hanall Biopharma (는) 각각 연간 69.6% 및 14.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 69.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11% 로 예상됩니다.

주요 정보

69.6%

수익 성장률

69.2%

EPS 성장률

Pharmaceuticals 수익 성장	36.0%
매출 성장률	14.9%
향후 자기자본 수익률	11.0%
애널리스트 커버리지	Low
마지막 업데이트	19 Jun 2024

최근 미래 성장 업데이트

Recent updates

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21

수익 및 매출 성장 예측

KOSE:A009420 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	208,400	45,825	51,025	54,625	4
12/31/2025	174,180	23,480	36,000	32,600	5
12/31/2024	147,120	10,760	25,633	19,220	5
3/31/2024	140,199	4,439	11,622	22,456	N/A
12/31/2023	134,910	3,509	20,445	29,643	N/A
9/30/2023	133,308	6,049	20,476	29,993	N/A
6/30/2023	129,981	6,464	2,734	10,524	N/A
3/31/2023	114,812	-919	10,130	18,084	N/A
12/31/2022	109,995	251	17,587	25,264	N/A
9/30/2022	104,764	-376	10,636	20,123	N/A
6/30/2022	100,596	949	10,515	20,067	N/A
3/31/2022	97,783	4,288	1,719	12,083	N/A
12/31/2021	101,594	8,896	-8,162	840	N/A
9/30/2021	98,500	16,123	72	6,659	N/A
6/30/2021	95,140	17,778	-4,183	1,719	N/A
3/31/2021	94,304	20,413	-5,913	1,778	N/A
12/31/2020	88,602	19,765	-6,460	929	N/A
9/30/2020	92,953	19,714	-20,156	-7,468	N/A
6/30/2020	98,834	21,457	1,452	14,085	N/A
3/31/2020	106,049	19,753	13,739	22,030	N/A
12/31/2019	108,452	19,174	12,215	20,491	N/A
9/30/2019	105,550	10,279	22,576	24,374	N/A
6/30/2019	101,531	7,373	10,174	11,694	N/A
3/31/2019	94,252	5,882	3,130	5,117	N/A
12/31/2018	91,839	3,300	-4,913	-2,994	N/A
9/30/2018	88,551	9,000	26,226	28,359	N/A
6/30/2018	89,131	9,149	26,945	28,894	N/A
3/31/2018	87,204	6,945	31,363	33,291	N/A
12/31/2017	84,231	5,813	N/A	42,139	N/A
9/30/2017	85,417	3,586	N/A	7,912	N/A
6/30/2017	81,809	562	N/A	-325	N/A
3/31/2017	81,807	1,355	N/A	2,825	N/A
12/31/2016	82,882	2,026	N/A	3,950	N/A
9/30/2016	82,223	-3,478	N/A	6,046	N/A
6/30/2016	79,584	-5,817	N/A	6,546	N/A
3/31/2016	79,447	-7,142	N/A	2,205	N/A
12/31/2015	80,023	-7,077	N/A	-454	N/A
9/30/2015	79,818	-16,050	N/A	1,128	N/A
6/30/2015	81,892	-13,143	N/A	280	N/A
3/31/2015	81,657	-12,865	N/A	-1,115	N/A
12/31/2014	80,880	-12,658	N/A	-3,518	N/A
9/30/2014	78,763	-11,694	N/A	-6,993	N/A
6/30/2014	77,511	-17,134	N/A	-5,677	N/A
3/31/2014	76,276	-18,966	N/A	-8,556	N/A
12/31/2013	74,228	-21,499	N/A	-7,780	N/A
9/30/2013	74,338	-9,978	N/A	-8,969	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A009420 의 연간 예상 수익 증가율( 69.6% )이 saving rate( 2.5% 보다 높습니다. ).

수익 vs 시장: A009420 의 연간 수익( 69.6% ) KR 시장( 28.8% 보다 빠르게 성장할 것으로 예상됩니다. 28.8% 연간).

고성장 수익: A009420 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: A009420 의 수익(연간 14.9% ) KR 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: A009420 의 수익(연간 14.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A009420 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 11 %).

Hanall Biopharma 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 45%, revenue upgraded

Consensus EPS estimates fall by 12%

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

Price target increased by 14% to ₩35,800

Recent updates

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견